Eledon Pharmaceuticals (ELDN) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 18, 2026, at the company's Irvine, CA office.

• Proxy materials, including the notice, proxy statement, and annual report, are available online for review and voting.

Voting matters and shareholder proposals

• Election of three Class III directors: David-Alexandre C. Gros, M.D., Jan Hillson, M.D., and James Robinson.

• Proposal to amend the Restated Certificate of Incorporation to increase authorized common stock from 300,000,000 to 450,000,000.

• Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

Board of directors and corporate governance

• Board recommends voting FOR all three proposals on the agenda.